iwCLL 2023 | Improved clinical outcomes in CLL when switching from covalent BTKi to a BCL2i following intolerance

In this interview, Mazyar Shadman, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, comments on the improved clinical outcomes observed in the real-world setting when chronic lymphocytic leukemia (CLL) patients who experience intolerance to a covalent BTK inhibitor (BTKi) are treated with a BCL2 inhibitor (BCL2i), namely venetoclax. This method appears to confer improved efficacy when compared to patients who are treated with a different BTKi after intolerance to the prior BTKi treatment. Dr Shadman highlights the need for prospective randomized trials to investigate this further, as although real-world observations are valuable to furthering understanding, this data is subject to a bias. This interview took place at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2023 meeting, held in Boston, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.